Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ANGELES , Dec. 8, 2016  Hanson ... manufacturing of dissolution testing and diffusion testing instruments ... been acquired by Teledyne Instruments, Inc. ("Teledyne"). The ... long-proven line of precision testing instruments, as well ... accelerating development of new products and services. ...
(Date:12/8/2016)... CANTEL MEDICAL CORP. (NYSE: CMD ) ... per diluted share, on a 22.1% increase in sales to ... 2016. This compares with net income of $14,254,000, or $0.34 ... quarter ended October 31, 2015. Non-GAAP net ... 2016 to $21,323,000, or $0.51 per diluted share, compared with ...
(Date:12/8/2016)... and SAN DIEGO , Dec. 8, 2016 ... solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech ... and the Genome Institute of Singapore ... new joint venture between Novogene and AITbiotech – will establish ... Singapore .   The new centre ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... The Dan Carlisle Agency, an Alabama-owned firm ... announcing the launch of a charity drive to raise support and awareness for ... children in Birmingham has grown steadily since the 1980’s, and the Pathways organization ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family owned ... and around the Hancock County area, is announcing the launch of a charity effort ... The Hancock County Food Pantry has worked for more than 30 years to meet ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry ... Control through a new partnership with Splashtop Inc. This remote control for Android ... to help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise ...
Breaking Medicine News(10 mins):